The qPCR Reagents Market size in North America was valued at USD 0.59 billion in 2024 and is estimated to be growing at a CAGR of 7.15% and worth USD 0.83 billion by 2029.
Rising patient populations for infectious diseases and genetic disorders, technological advancements in the life sciences sector, increasing investments, funds, aging population, and grants for PCR-based research, and the successful completion of the human genome project contribute to North America QPCR reagents market growth. Among this rising prevalence of infectious and genetic diseases has raised the demand for diagnostic tests to assist people in taking preventative measures. In addition, the need for genetic testing has increased as the senior population has grown. In the last ten years, a slew of genome projects has been launched. Researchers have gained a better understanding of the human genome as a result of this. These demands have aided the development of qPCR equipment, which has raised the market for qPCR equipment.
Increased governmental and commercial financing, as well as an increase in the number of research grants, are helping to advance gene-based research (such as qPCR and dPCR) in North America. Due to increased usage in scientific fields such as forensic science, human genetic testing, and pathogen detection, the market is projected to develop significantly. Players will have incremental opportunities to grow their market share in the future years as their veterinary medicine and food microbiology applications expand. The usage of clinical diagnostic tests will rise due to the increased frequency of target illnesses and the demonstrated efficiency of real-time PCR (qPCR) analysis in estimating and identifying disease-causing microorganisms. As a result, the real-time PCR (qPCR) industry is projected to develop faster in North America.
The market's growth has been hampered by the high cost of qPCR equipment and a lack of high-level technical skills to operate qPCR equipment. In addition, the level of selectivity is a significant problem for qPCR. An optimized real-time PCR test has a high technical sensitivity, but the maximum input of DNA during sample preparation and per PCR reaction is the limiting step. These drawbacks are a significant setback. As a result, it is expected to hinder market growth.
This research report on the North America qPCR reagents market has been segmented and sub-segmented into the following categories:
By Detection Method:
By Packaging Type:
By End User:
By Application:
By Country:
During the forecast period, the North American qPCR reagents market is anticipated to have the largest share of the global qPCR reagents market. The growth of the North American market is being driven by factors such as high penetration of qPCR technologies among key end-users, increasing public and private funding to expand the application base of qPCR, ongoing product advancements in the field of qPCR reagents, and continuous reductions in the average cost of genome sequencing. The healthcare system in the United States is well-developed and well-structured. In addition, the system promotes research and development. These policies encourage international companies to invest in the United States and, eventually, the North American market. As a result, numerous market players have taken up residence in this region. In addition, infectious disease prevalence is also high in the United States and Mexico. This has resulted in a surge in demand for qPCR diagnostic tests, driving up demand for qPCR reagents.
KEY MARKET PLAYERS:
A few of the notable players operating in the North America qPCR reagents market are Thermo Fisher Scientific, Bio-Rad Laboratories, Qiagen N.V., F. Hoffmann-La Roche, Agilent Technologies Inc., Takara Bio, Affymetrix Inc., Promega Corporation, Sigma-Aldrich Corporation, and Quanta Biosciences.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region